Personalized antisense oligonucleotide therapy (TARDBP-targeted ASO)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Personalized antisense oligonucleotide therapy (TARDBP-targeted ASO), covering 2026-04-09 to 2026-04-09. Get the full timeline:
Most recent: Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS [Phase 1, Phase 2]